Existing horizon scanning activities could be strengthened to aid budget planning in the context of high upfront cost therapies such as gene therapies. International collaborations could be leveraged ...

The Office of Health Economics is delighted to host the Health Economists’ Study Group Summer Meeting, which will run from 30th June – 2nd July 2025. Founded in 1972, the Health Economists’ Study ...

Patrick Holmes is an industry veteran with over 30 years of experience in the pharmaceutical industry in a broad range of roles, most notably in the global policy arena. Patrick is the Science and ...

Andrew is a leading expert in health economic evaluation, with a particular focus on statistical methods for cost-effectiveness analysis. His work encompasses parameter estimation for economic models, ...

Measuring and valuing health outcomes is arguably what makes health economics such a unique and sometimes controversial discipline. The idea of putting a numerical value on an individual’s health ...

Today marks Rare Disease Day 2025. This time last year we published an Article entitled “Why do we care about rare?”, summarising the origins of rare disease day, the fundamental ambition – to strive ...

Alastair Fischer Ph.D. has had a long career in statistics, economics and public health. He has a BSc from the University of Adelaide majoring in Pure Mathematica and Statistics, a BEc from the ...

Matthias is a Principal Economist at OHE. His expertise and research interests include regulatory science and policy, the value of pharmaceuticals for patients and society, and the economics of ...

Sulayman’s skills include health economic theory and economic modelling with a particular aptitude for econometric analysis and quantitative data. His primary ...